NCT01525082View on ClinicalTrials.gov

Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

January 31, 2018

Study Completion Date

December 31, 2019

Conditions
GastrinomaGlucagonomaInsulinomaPancreatic Polypeptide TumorRecurrent Islet Cell CarcinomaRecurrent Pancreatic CancerSomatostatinomaStage III Pancreatic CancerStage IV Pancreatic Cancer
Interventions
DRUG

Capecitabine

Capecitabine by mouth twice daily on Days 1 to 14

DRUG

Temozolomide

Temozolomide by mouth daily on Days 10 to 14

BIOLOGICAL

Bevacizumab

Bevacizumab IV over 30 to 90 minutes on Days 1 \& 15

Trial Locations (1)

94305

Stanford University Medical Center, Stanford

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Shaheen Shagufta

OTHER

NCT01525082 - Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter